Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
about
Quality of Life Measurements: Any Value for Clinical Practice?Patient-generated health data: a pathway to enhanced long-term cancer survivorship.Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials.Outcomes of Six-Dose High-Dose Cytarabine as a Salvage Regimen for Patients with Relapsed/Refractory Acute Myeloid Leukemia.Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care DeliveryLinguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse EventValidation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™).Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer.Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.Chemotherapy-induced peripheral neuropathy: Current status and progress.Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical TrialsAn explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma.Effects of survivin on FVADT chemotherapy for refractory multiple myeloma.Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first-line therapy for BRAF-mutated metastatic melanoma.Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiativeExploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial settingR-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology.Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma.Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry.Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.Asking the right questions to get the right answers: using cognitive interviews to review the acceptability, comprehension and clinical meaningfulness of patient self-report adverse event items in oncology patients.The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012.Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials.Treatment-associated toxicities reported by patients with early-stage invasive breast cancer.The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry.Patient-Reported Physical Function Measures in Cancer Clinical Trials.Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications.Symptoms, Quality of Life, and Daily Activities in People With Newly Diagnosed Solid Tumors Presenting to a Medical Oncologist.Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer.Toxicity-Related Factors Associated With Use of Services Among Community Oncology Patients.Patient-relevant outcomes associated with generic tamsulosin, levothyroxine and amphetamine in the FDA Adverse Event Reporting System: a pilot study.Peripheral nervous system injury after high-dose single-fraction image-guided stereotactic radiosurgery for spine tumors.Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitisNews from the NIH: Person-centered outcomes measurement: NIH-supported measurement systems to evaluate self-assessed health, functional performance, and symptomatic toxicity.Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.
P2860
Q30234561-BE6313A4-3A70-4C31-A969-4B38BE6418D6Q31034369-75195672-946E-401A-B191-3FE4ABBF8881Q31160832-CE302EF4-67C6-4AAD-9FE8-AB006E6117EAQ33734101-5CCFEA4A-408B-4779-9250-215C24B6B543Q33858387-72A57984-45E4-4C8B-85E0-95460987655AQ33900714-75344730-B11D-43F9-84A4-05DBFECE50E9Q35912506-DC31CD41-63B7-4AA3-BAFC-5B99976B01F3Q35927927-530A02EB-E4FC-4AF0-8B88-55096767C06FQ36147112-560152D2-7151-4DF9-8024-B5CE4395FE18Q36243479-DAA068EB-60BF-4347-A259-C680638049A9Q36381727-8D4C6997-6EF5-42BA-BB46-9E0022C11063Q36421901-1CBDF3BF-CDDC-44F9-987A-78418A36BDBEQ36854151-055AE1FC-CC5B-4A22-9091-50F498773A8DQ37063738-107ADF4B-B649-405A-A088-BAEC6CA48587Q37108574-E9202B63-F810-48FC-9EF6-BA4ED3CC0AB0Q37287433-E37F1E35-74DA-4C34-8D9F-99070FBBCDC0Q37635557-8490EFA2-6A69-4969-8414-A45E2A99F730Q37706400-060B8C07-BCAD-41FA-90DB-DD93AD1289A7Q37735424-C293FE4D-211C-449D-9FE0-10B4ACABC1ACQ38383826-2C326BC0-2489-46C4-A673-1E5F82F678DBQ38606464-363ABFFC-EEF1-40E3-952E-0ECEA2F720CBQ38716340-45A4EFA9-675A-4AD3-A0BA-50A06AE63571Q38747276-65C21543-EAF6-40A0-9772-F77EFCEE73E9Q38828759-4B84214C-1ED5-46F6-AE5C-F171BBE4F3BDQ38853323-ADC082B6-6BFA-47D3-8820-D00E4EDA48B5Q38859560-4A0D0025-7C3A-4DFE-B588-1381C627F80EQ38937757-C71807C3-2847-4877-AF43-2BFC1DEAA307Q38957147-6C701CBB-2A62-48A9-83C1-CBDEAF54EE49Q39002082-AD6193E5-F1C7-404C-BAAB-C60A325BDD9AQ39003028-67451802-4B41-4750-9405-94B0AA2CFB83Q39270037-A95EA116-46A8-4259-A550-A9741C95899CQ39285061-F4466175-AEA4-4806-93C0-99D417E5FBC2Q39741366-608C5DDC-419B-45B7-95AE-AA100568E68AQ39791477-0AFD6C00-FDD3-41E5-89EE-82553EC72125Q40097166-DBC0037A-C795-4262-838D-094E42C8712FQ40132052-FBDEF01C-832B-4966-9C9B-C83E4B67985BQ40314416-3DE7052A-03AA-4F14-8DF4-5FCA36926F09Q41513645-82459B52-A6FF-45E9-8BEC-D744681C091CQ42352132-32E2D677-BA18-4FBD-B2AC-8805E059E7E0Q45872843-F6CE5353-C827-4852-BB7C-0BEE85BBDCA1
P2860
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Validity and Reliability of th ...... for Adverse Events (PRO-CTCAE)
@en
type
label
Validity and Reliability of th ...... for Adverse Events (PRO-CTCAE)
@en
prefLabel
Validity and Reliability of th ...... for Adverse Events (PRO-CTCAE)
@en
P2093
P2860
P1433
P1476
Validity and Reliability of th ...... for Adverse Events (PRO-CTCAE)
@en
P2093
Amylou C Dueck
Andrea M Denicoff
Ann M O'Mara
Antonia V Bennett
Bryce B Reeve
Charles S Cleeland
Deborah Schrag
Deborah W Bruner
Diane B Paul
Donna M Bryant
P2860
P304
P356
10.1001/JAMAONCOL.2015.2639
P577
2015-08-13T00:00:00Z